Lisdexamfetamine dimesylate
SPD489-405
Approved small_molecule completed
Quick answer
Lisdexamfetamine dimesylate for Attention-deficit/Hyperactivity Disorder is a Approved program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 3 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Attention-deficit/Hyperactivity Disorder
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed